English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe University of Texas MD Anderson Cancer Center and RUSH University System for Health today announced a partnership to create RUSH MD Anderson Cancer Center.
Tag: MD Anderson Cancer Center
MD Anderson and CureVac enter strategic collaboration to develop novel cancer vaccines
MD Anderson and CureVac today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
Radiation before mastectomy cuts time delays for reconstructive surgery in breast cancer patients
Researchers at The University of Texas MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays and improved patient satisfaction.
AACR: MD Anderson’s Padmanee Sharma elected Fellow of the AACR Academy
Padmanee Sharma, M.D., Ph.D., associate vice president of Immunobiology, professor of Genitourinary Medical Oncology and Immunology, and director of scientific programs for the James P. Allison Institute at The University of Texas MD Anderson Cancer Center, has been elected to the 2024 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of her work to establish and advance immune checkpoint therapies as effective treatments for patients with a variety of cancers.
MD Anderson’s Institute for Data Science in Oncology announces appointment of inaugural IDSO Affiliates
MD Anderson’s Institute for Data Science in Oncology today announced the appointment of its inaugural cohort of 33 IDSO Affiliates, who bring diverse expertise to advance the work of the institute and foster the data science ecosystem at MD Anderson.
MD Anderson acquires inducible switch technologies for cell therapy
MD Anderson has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDE switch and GoCAR platforms. As a result, MD Anderson may incorporate these technologies into its own cell therapy programs as well as make them available for licensing to interested parties.
MD Anderson and C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy
MD Anderso and C-Biomex today announced a strategic collaboration to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
MD Anderson designated IAEA Collaborating Centre to focus on improving radiation, radiology and nuclear medicine worldwide
The University of Texas MD Anderson Cancer Center today announced the signing of an agreement with the International Atomic Energy Agency (IAEA) to become an IAEA Collaborating Centre.
American Thyroid Association® Announces New Board of Directors
Michael McDermott, MD Installed as President
Christopher McCabe, PhD Installed as Secretary
ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy alone
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further benefits gained from the addition of the PARP inhibitor olaparib in maintenance setting, according to researchers from The University of Texas MD Anderson Cancer Center.
Alejandro Aballay, Pharm.D., Ph.D., named Dean of MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences
Alejandro Aballay, Pharm.D., Ph.D., a national leader in immune signaling and graduate education, has been named dean of the MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, effective Jan. 2, 2024.
MD Anderson and Panacea launch Manaolana Oncology to develop antibody-based therapies for cancer
MD Anderson and Panacea Venture announced the launch of Manaolana Oncology, a new company created to develop and advance antibody-based therapies against novel cancer targets.
University of Texas System Regents announce plans to build UT Medical Center on site of Erwin Center
Today The University of Texas System Board of Regents Chairman Kevin P. Eltife announced plans to launch a monumental healthcare initiative to accelerate and expand UT Austin’s burgeoning medical district into a world-class academic medical center for education, research and patient care. The University of Texas at Austin Medical Center will start with two new hospital towers — The University of Texas MD Anderson Cancer Center and a UT Austin hospital. MD Anderson, the nation’s #1 cancer hospital, will expand its Houston footprint to Austin by building and operating a new, comprehensive cancer center, while UT Austin will build and operate its new specialty hospital.
New single-cell study provides novel insights into gastric cancer
A single-cell study led by MD Anderson researchers and published in Cancer Cell provides a deeper understanding of the evolution of the tumor microenvironment during gastric cancer progression.
Blood test aids in predicting lung cancer mortality risk
A blood-based four-protein panel (4MP), when combined with a lung cancer risk model (PLCOm2012), can better identify those at high risk of dying from lung cancer than the current U.S. Preventive Services Task Force (USPSTF) criteria.
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for sarcoma
MD Anderson and Replay announced that the FDA has issued a ‘safe to proceed’ for the Investigational New Drug application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for sarcoma.
Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial, published today in The Lancet, were first presented at the European Society for Medical Oncology (ESMO) Congress 2022.
ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations
Three clinical trials led by MD Anderson researchers showed positive results with the targeted therapy erdafitinib for patients with FGFR-altered tumors. The data were presented at the 2023 ASCO Annual Meeting.
ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
An MD Anderson-led Phase II trial showed the HER2-targeted therapy zanidatamab demonstrated durable responses in patients with advanced HER2-positive biliary tract cancer. The data were presented at the 2023 ASCO Annual Meeting.
MD Anderson researchers Helen Piwnica-Worms and Richard Wood elected to National Academy of Sciences
Two MD Anderson researchers, Helen Piwnica-Worms, Ph.D., and Richard Wood, Ph.D., have been elected to the prestigious National Academy of Sciences for their respective contributions to advancing our understanding of cancer genetics, biochemistry and cell biology.
MD Anderson and Generate:Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI
MD Anderson and Generate:Biomedicines announced a co-development and commercialization agreement to accelerate novel protein therapies using generative AI.
AACR: Mutations in three key genes associated with poor outcomes in lung cancer patients treated with KRAS G12C inhibitors
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered that co-occurring mutations in three tumor suppressor genes – KEAP1, SMARCA4 and CDKN2A – are linked with poor clinical outcomes in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitors adagrasib or sotorasib.
AACR: Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023.
Kerin Adelson, M.D., named MD Anderson Chief Quality and Value Officer
MD Anderson announced Kerin Adelson, M.D., as the institution’s chief quality and value officer. Adelson is an accomplished clinician and researcher with extensive leadership experience in delivering high-quality and value-based cancer care.
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.
MD Anderson and Xilis announce strategic collaboration to advance novel technology and accelerate therapeutic development
MD Anderson and Xilis announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere technology in support of preclinical research to accelerate the development of novel cancer therapies.
MD Anderson and KKR-backed Replay form new product company Syena to pioneer first-in-class TCR NK cell therapy
MD Anderson and Replay announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) natural killer (NK) cell therapies.
MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers
MD Anderson and Federation Bio announced a strategic collaboration to design and manufacture a synthetic microbial consortium with the goal of improving responses in immunotherapy-resistant cancers.
MD Anderson EGFR Classification licensed by BostonGene and Tempus to provide new insight on atypical mutations in lung cancer
MD Anderson announced licensing agreements with BostonGene and Tempus for the MD Anderson EGFR Classification, which organizes EGFR mutations into subgroups that may guide clinical decision-making.
MD Anderson Research Highlights: SABCS 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into basic, translational and clinical cancer research from MD Anderson experts. This special edition features breast cancer presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS) focused on the combination of everolimus and hormone therapy, a new driver for brain metastases in inflammatory breast cancer, improving treatment for men with breast cancer, and a new understanding of the importance of HER2 expression for patients with early-stage triple-negative breast cancers.
Andrew Sabin Family Foundation doubles down on commitment to end cancer with $10M gift
The University of Texas MD Anderson Cancer Center today announced a $10 million gift to the James P. Allison Institute from the Andrew Sabin Family Foundation and Andrew “Andy” Sabin, a senior member of the MD Anderson Cancer Center Board of Visitors (BOV). The gift is the philanthropist’s second multimillion-dollar commitment to MD Anderson in less than 10 years.
MD Anderson and Exscientia launch strategic collaboration to leverage AI in developing novel oncology treatments
MD Anderson and Exscientia today announced a strategic collaboration to align the drug development expertise of MD Anderson with the patient-centric AI capabilities of Exscientia to advance new targeted cancer therapies.
Eyal Gottlieb, Ph.D., to join MD Anderson as Vice President for Research
Eyal Gottlieb, Ph.D., has been named MD Anderson’s vice president for Research. Gottlieb, an accomplished scientist and leader, will join the institution in January to uphold and expand the institution’s research excellence.
MD Anderson Research Highlights: SITC 2022 Special Edition
This special edition features upcoming presentations by MD Anderson researchers at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, including immunotherapy advances in human papillomavirus (HPV)-positive head and neck cancers, microbiome signatures linked with specialized immune-cell clusters, and promising early activity from novel immunotherapy drugs in advanced melanoma and colorectal cancer.
Cancer survivors, supporters rally for in-person return of MD Anderson’s Boot Walk to End Cancer®
Thousands are expected at MD Anderson’s Boot Walk to End Cancer® on Saturday, Nov. 5, as The University of Texas MD Anderson Cancer Center prepares for the in-person return of the seventh annual event in the Texas Medical Center.
Metastasis-directed radiation therapy plus hormone therapy improves progression-free survival for men with advanced prostate cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were presented today at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.
Response-adapted ultra-low dose radiation achieves complete response in 90% of patients with orbital indolent B-cell lymphomas
Using a novel response-adapted ultra-low dose radiation therapy strategy, MD Anderson researchers observed a 90% complete response rate in patients with orbital indolent B-cell lymphoma. The results were presented today at the 2022 ASTRO Annual Meeting.
Allison Institute establishes internal advisory council of MD Anderson experts
MD Anderson’s James P. Allison institute today announced the establishment of its internal advisory council to provide scientific input and to align the work of the institute with the broader MD Anderson research enterprise.
MD Anderson and ARTIDIS announce strategic alliance to advance nanomechanical technology platform for optimizing cancer treatment
MD Anderson and ARTIDIS today announced a strategic alliance to investigate ARTIDIS nanotechnology platform as a treatment-optimization tool for patients with solid tumors.
MD Anderson and Radiopharm Theranostics launch joint venture to develop novel radiopharmaceuticals
MD Anderson and Radiopharm Theranostics today announced the launch of Radiopharm Ventures, LLC, a joint venture created to develop novel radiopharmaceutical therapeutic products for cancer.
Tumor-infiltrating B cells and plasma cells influence early-stage lung cancer biology, immunotherapy responses
MD Anderson researchers used extensive single-cell analysis to create a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, revealing new roles for these immune cells in cancer development and immunotherapy responses.
Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial were presented today at the European Society for Medical Oncology (ESMO) Congress 2022.
HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2022.
MD Anderson and Virogin Biotech announce strategic collaboration to accelerate oncolytic virus research and development for treating advanced cancers
MD Anderson and Virogin Biotech today announced a strategic collaboration to accelerate the development of oncolytic virus therapies for advanced cancers.
MD Anderson and Erasca announce strategic research and development collaboration in RAS/MAPK-driven cancers
MD Anderson and Erasca announced a strategic research and development collaboration to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway in cancer.
Pralsetinib achieves tissue-agnostic benefits for patients with RET gene fusions
The targeted therapy pralsetinib was well-tolerated and demonstrated high response rates in patients with RET gene fusions regardless of tumor type, according to results from the Phase I/II ARROW trial.
MD Anderson and Empyrean announce agreement to develop novel radiation therapy technologies
MD Anderson and Empyrean announced an exclusive license and joint development agreement to advance new technologies and products in radiation oncology.
MD Anderson and TransCode Therapeutics announce strategic alliance to advance RNA therapies for oncology
MD Anderson and TransCode announced a strategic alliance to advance TransCode’s pipeline of RNA-targeted therapeutic and diagnostic candidates for oncology.
MD Anderson to host virtual Cancer Neuroscience Symposium
MD Anderson will host the virtual Cancer Neuroscience Symposium Sept. 22-23, 2022, in collaboration with the journal Advanced Biology. The symposium is free to attend and gathers leading experts in the field to discuss a variety of topics on the relationship between cancer biology and neuroscience. Registration includes the opportunity to participate in an abstract competition and to view sessions following the event.
MD Anderson Research Highlights for July 27, 2022
Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients with lateral pelvic lymph node metastases in rectal cancer. Laboratory findings offer new understanding of the pancreatic cancer immune microenvironment, melanoma cell states, TP53 mutation status in acute myeloid leukemia (AML), and potential targets for metastatic prostate cancer and GNAS-mutant colorectal cancer.